Definition
Tuvirumab is a human monoclonal antibody developed for the therapeutic management of chronic hepatitis B infection. It is designed to bind the hepatitis B virus surface antigen (HBsAg) and neutralize circulating viral particles.
Overview
Tuvirumab was investigated in early‑stage clinical trials, completing a Phase I safety and pharmacokinetic study in 2001. The antibody was evaluated both as monotherapy and in combination with interferon‑α2b or lamivudine in small cohorts of chronic hepatitis B carriers. Although the trials demonstrated the feasibility of intravenous administration and the formation of immune complexes with HBsAg, the drug has not progressed to later‑phase development and is not currently approved for clinical use.
Etymology / Origin
The name follows the International Nonproprietary Names (INN) convention for monoclonal antibodies, ending in the suffix “‑mab” to denote “monoclonal antibody.” The prefix “Tuvir‑” is a non‑descriptive, arbitrary stem assigned during the naming process; no specific linguistic meaning has been published. The antibody was originally discovered and developed by Novartis Pharma AG.
Characteristics
| Attribute | Details |
|---|---|
| Type | Human monoclonal immunoglobulin G (IgG) antibody |
| Source | Fully human (derived from human immunoglobulin gene libraries) |
| Target | Hepatitis B virus surface antigen (HBsAg), specifically the conserved “a‑determinant” |
| Mechanism of Action | Binds HBsAg, forming immune complexes that neutralize circulating virions and may facilitate clearance by the reticuloendothelial system |
| Clinical Status | Investigational; completed Phase I trials (2001) with no subsequent approvals |
| Regulatory Identifiers | CAS Number 138660‑97‑6; UNII 31Z0AB5WNC; ATC code none |
| Administration | Intravenous infusion |
| Key Publications | – Heijtink R.A. et al., J. Med. Virol. 2001 – pharmacokinetic monitoring of Tuvirumab in chronic HBV patients. – van Nunen A.B. et al., Liver 2001 – safety and efficacy assessment of an intravenous anti‑HBs monoclonal antibody. |
Related Topics
- Hepatitis B virus (HBV) – a DNA virus that causes acute and chronic liver disease.
- HBsAg (hepatitis B surface antigen) – the major viral envelope protein targeted by neutralizing antibodies.
- Monoclonic antibody therapy for infectious diseases – a growing field that includes agents such as libivirumab, ansuvimab, and bamlanivimab.
- Antiviral agents for HBV – nucleos(t)ide analogues (e.g., lamivudine, tenofovir) and immune modulators (e.g., interferon‑α).
- INN naming conventions for antibodies – the systematic approach to assigning non‑proprietary names (e.g., suffix “‑mab”).
Accurate information is based on peer‑reviewed literature and publicly available drug databases as of 2024.